Oxford/AstraZeneca vaccine effective against UK variant, researchers say
University of Oxford researchers said Friday that the COVID-19 vaccine they developed with British-Swedish pharmaceutical giant AstraZeneca remains effective against a new, more contagious variant of the novel coronavirus currently circulating in the United Kingdom.
A preprint of ongoing work to assess effectiveness of the Oxford/AstraZeneca vaccine shows that the existing version has similar efficacy against the so-called B117 variant to previously circulating variants. The preprint also describes recent analysis showing that the vaccination "results in a reduction in the duration of shedding and viral load, which may translate into a reduced transmission of the disease," according to a press release from the university.
"Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B117, which caused the surge in disease from the end of 2020 across the UK," Andrew Pollard, professor of pediatric infection and immunity at the University of Oxford and chief investigator on the Oxford vaccine trial, said in a statement.
The B117 variant was first identified last September in Kent, England, and has since spread to dozens of other countries.
"We are working with AstraZeneca to optimize the pipeline required for a strain change should one become necessary," Sarah Gilbert, professor of vaccinology at the University of Oxford and chief investigator on the Oxford vaccine trial, said in a statement. "This is the same issue that is faced by all of the vaccine developers, and we will continue to monitor the emergence of new variants that arise in readiness for a future strain change."